COMMUNIQUÉS West-GlobeNewswire

EHS Opens Walsh Ambulatory Pavilion, Expanding Access to Advanced Outpatient Care
29/04/2026
FAR ROCKAWAY, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Episcopal Health Services (EHS) proudly announces the opening of the Walsh Ambulatory Pavilion, a 65,000-square-foot, state-of-the-art outpatient facility located [...]
CMR Surgical Submits 510(k) Application to U.S. FDA to Expand Versius Plus™ into Gynecology
29/04/2026
PRESS RELEASE Following Recent FDA Clearance for Cholecystectomy, the Company is now 510(k) pending for Gynecology. This Submission Builds On Extensive Global Clinical Experience in Gynecology and Continues CMR’s U.S. [...]
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
29/04/2026
MOUNTAIN VIEW, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies and commercializing [...]
Tacalyx Secures €11 Million to Advance Lead TACA-Targeting ADC Programme Toward the Clinic
29/04/2026
Tacalyx Secures €11 Million to Advance Lead TACA-Targeting ADC Programme Toward the Clinic Berlin, Germany, April 29, 2026 (GLOBE NEWSWIRE) -- Tacalyx, a leader in the discovery and development of cancer therapies [...]
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
29/04/2026
NOVATO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra [...]
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
29/04/2026
Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory Momentum Seven Approved Phase 2a Human Clinical Trials Expected to Begin Patient [...]
DLH to Announce Fiscal 2026 Second Quarter Financial Results
29/04/2026
ATLANTA, April 29, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital [...]
Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
29/04/2026
Real-world clinical experience with the novel IBS-specific guided diagnostic therapy to be presented at the world’s largest GI medical conference, May 2–5, 2026, in Chicago IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE [...]
Beacon Therapeutics Annouces Presentations at the ARVO 2026 Annual Meeting
29/04/2026
LONDON and CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (Beacon Therapeutics or the Company), a leading clinical-stage biotechnology company with a mission to save and [...]
Picard Medical / SynCardia Featured in Interview Series with The Mullings Group
29/04/2026
– Discussions to highlight total artificial heart therapy, advanced heart failure market, and next-generation platform development – TUCSON, Ariz., April 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American [...]
TOMI Environmental Solutions Targets $70 Billion U.S. Drone and Defense Budget with Autonomous SteraMist iHP Decontamination
29/04/2026
Strategic Initiative Focuses on Automated Biological and Chemical Defense for Land, Air, Sea, and Space FREDERICK, Md., April 29, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a [...]
GH Research Announces Pricing of $117.5 Million Underwritten Offering
29/04/2026
DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in [...]
Laguna Announces FDA Clearance of IND Application for LGNA-100, a Novel γδ T Cell Activator for High-Risk Pediatric Leukemias
29/04/2026
SAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) -- Laguna Biotherapeutics, Inc. (Laguna), a clinical-stage biotechnology company focused on novel live bacterial therapeutics, today announced that the U.S. Food and Drug [...]
Codexis to share RNA manufacturing advances at TIDES USA
29/04/2026
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, will present new data on ECO [...]
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
29/04/2026
DALLAS, April 29, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene [...]
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
29/04/2026
EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA submission in Q4 2026 NEEDHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Candel [...]
ORYZON to Participate in Upcoming Events in May and June
29/04/2026
Updated data from iadademstat’s clinical trials in acute myeloid leukemia to be presented at EHA-2026 in June MADRID and CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: [...]
Imviva Biotech to Present Clinical Data from Ongoing Phase 1/2 Study of CTA313 at the American Society of Gene & Cell Therapy's Annual Meeting
29/04/2026
Dual-targeted allogeneic CAR-T therapy demonstrates immune-reset mechanism and durable remission in system lupus erythematosus BOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology [...]
Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market
29/04/2026
Sangamo’s common stock to transition trading from The Nasdaq Capital Market to OTCQB Venture Market beginning May 5, 2026 RICHMOND, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a [...]

Pages